Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company’s CRISPR-based ...

For years, Yale researchers David Breslow and Mustafa Khokha have worked together with a similar challenge in their ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Researchers used CRISPR to change the number of chromosomes in Arabidopsis by fusing chromosome arms, reducing the genome ...

In a groundbreaking fusion of artificial intelligence and gene editing, researchers are leveraging machine learning to enhance CRISPR technology’s precision and efficiency. This integration is opening ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the most oversold biotech stocks to invest in. Following the company’s third-quarter financial results, Oppenheimer reaffirmed its Outperform rating ...

You've probably heard about the gene-editing technology CRISPR. The massive biotech breakthrough, which has emerged in the last decade, has mainly been touted for the ways it will let scientists edit ...

Goldenberries taste like a cross between pineapple and mango, pack the nutritional punch of a superfood, and are increasingly ...

The new GE technology — for which the Indian Council of Agricultural Research (ICAR) has recently been granted a patent — deploys the so-called TnpB or Transposon-associated proteins.